Skip to main content

Table 1 List of common serological tumor markers in clinical use that contain a glycan componenta

From: The sweet and sour of serological glycoprotein tumor biomarker quantification

Biomarker Type of detection Cancer type(s) Clinical applications References
AFP Protein and core fucosylation (for AFP-L3) Germ-cell hepatoma; non-seminomatous testicular carcinoma Diagnosis, staging. detecting recurrence, monitoring therapy [153, 154]
hCG Protein alone Testicular Diagnosis;staging; detecting recurrence; monitoring therapy [154, 155]
CA125 Protein alone Ovarian Prognosis; detecting recurrence; monitoring therapy [154, 156]
CA15-3 Sialylated O-glycan on MUC1 Breast Monitoring therapy [157159]
CA19-9 SLe on mucin glycoproteins and gangliosidesa Pancreatic Monitoring therapy [160, 161]
CEA Protein alone Colon Detecting recurrence; monitoring therapy [154, 157, 161]
HER2 Protein alone Breast Therapy selection [157, 162, 163]
PSA Protein alone Prostate Screening; diagnosis (with digital rectal examination) [154, 164]
Thyroglobulin Protein alone Thyroid Monitoring [165, 166]
CA27-29 MUC1 protein alone Breast Monitoring [161, 167]
  1. aModified and adapted from Kulasingam and Diamandis [168]. AFP, alpha-fetoprotein; CA, carcinoma antigen 15-3; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HER, herceptin; hCG, human chorionic gonadotropin; MRM, multiple reaction monitoring; PSA, prostate-specific antigen; SLe, sialyl Lewis antigen.